menu
    • menu

    Company profile for Ocular Therapeutix

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Our product pipeline candidates are designed to provide differentiated drug delivery solutions that reduce the complexity and burden of the current standard of...
    Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Our product pipeline candidates are designed to provide differentiated drug delivery solutions that reduce the complexity and burden of the current standard of care by creating sustained release alternatives.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ocular TherapeutixUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    15 Crosby Drive, Bedford, MA 01730, US
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ocutx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ocular Therapeutix Grants Inducement Under Nasdaq Rule 5635(c)(4)
    Ocular Therapeutix Grants Inducement Under Nasdaq Rule 5635(c)(4)

    05 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/05/3200584/0/en/Ocular-Therapeutix-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    05 Dec 2025
    Share Share
    Ocular Therapeutix Initiate 1st Patient Randomization in HELIOS-3
    Ocular Therapeutix Initiate 1st Patient Randomization in HELIOS-3

    24 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/24/3193355/0/en/Ocular-Therapeutix-Announces-First-Patient-Randomized-in-HELIOS-3-Phase-3-Registrational-Program-for-AXPAXLI-in-NPDR.html

    GLOBENEWSWIRE
    24 Nov 2025
    Share Share
    Ocular Therapeutix Issues Inducement Grant Per Nasdaq LR
    Ocular Therapeutix Issues Inducement Grant Per Nasdaq LR

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183524/0/en/Ocular-Therapeutix-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Ocular Therapeutix Unveils Q3 2025 Financials & Business Update
    Ocular Therapeutix Unveils Q3 2025 Financials & Business Update

    04 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/04/3180179/0/en/Ocular-Therapeutix-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html

    GLOBENEWSWIRE
    04 Nov 2025
    Share Share
    Ocular Therapeutix To Release Q3 2025 Financial Results On Nov 4
    Ocular Therapeutix To Release Q3 2025 Financial Results On Nov 4

    28 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/28/3175233/0/en/Ocular-Therapeutix-to-Report-Third-Quarter-2025-Financial-Results-on-November-4-2025.html

    GLOBENEWSWIRE
    28 Oct 2025
    Share Share
    Ocular Therapeutix To Join Future Scientific Conferences
    Ocular Therapeutix To Join Future Scientific Conferences

    07 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/07/3162362/0/en/Ocular-Therapeutix-to-Participate-in-Upcoming-Scientific-Conferences.html

    GLOBENEWSWIRE
    07 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search